新辅助化疗免疫疗法用于患有局部高级可切除食道状细胞癌的老年患者
Jinlin Cao1, Zhengchao Xu1, Yuqian Zhang1
1Department of Thoracic surgery, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Annals of surgical oncology
|November 18, 2025
概括
新辅助免疫疗法与化疗 (NAIC) 结合改善了老年食道癌症患者的生存率. 这种安全的治疗提高了无病和整体存活率,即使在75岁以上的人群中也是如此.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 免疫治疗是一种免疫疗法.
背景情况:
- 食道状细胞癌 (ESCC) 在老年患者中构成挑战.
- 局部先进的切除性ESCC需要老年人有效的治疗策略.
研究的目的:
- 评估新辅助免疫疗法与化疗 (NAIC) 结合的新辅助免疫疗法的安全性和有效性,用于局部先进切除ESCC的老年患者.
- 为了在这个患者群体中比较NAIC加手术和单独手术之间的结果.
主要方法:
- 对278名年龄在70岁以上的患者进行了回顾性审查,他们患有局部发达可切除ESCC.
- 倾向性得分匹配比较和考克斯回归分析"仅手术"与"NAIC加手术"组.
- 对术后结果,生存率和不良事件的分析.
主要成果:
- 与单独手术相比,NAIC加手术显示出更高的无病生存率 (DFS) 和整体生存率 (OS).
- 老年患者 (>75岁) 的术后结果和并发症率相似,严重不良事件没有增加.
- 接受NAIC治疗的患者的主要病理反应独立地与改善的DFS和OS有关.
结论:
- NAIC加手术是一种安全有效的治疗方法,适用于患有局部先进切除ESCC的老年患者.
- 组合疗法改善了生存结果,包括在75岁以上的精选适合患者中.
- 在接受NAIC的患者中,获得重大病理反应对于长期存活至关重要.
相关概念视频
Barrett Esophagus-II: Clinical Manifestations and Management
746
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
746
Esophageal Varices-II: Clinical Features and Management
349
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
349
Esophageal Strictures-II: Clinical Features and Management
399
Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
399
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
578
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
578
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


